| Synonym |
| Thai / English name |
Part Used : ใบActivity : EFFECTS ON PHARMACOKINETICSolvent/Active Compound : Ginkgo biloba extraction (GBE)Type of experiment : humanType of animal : -Type of study : Open trialN(Total) : 10N(Treatment) : 10Sex : MaleAge : -Route : Oral administrationDose/Conc.(herb) : GBE intake 360 mg/dDuration : 28 daysType of interaction : PharmacokineticsInteraction with drug : Midazolam*/Versed/DormicumDose/Conc.(drug) : -Result : PositiveRemark : - Midazolam 8 mg were orally administered to 10 male healthy volunteers before and after GBE intake. - AUC0-alpha for midazolam was singnificantly (25%) increased by GBE intake and oral clearance was significantly (26%) decreased.Note : - Data incomplete
Part Used : ใบActivity : EFFECTS ON PHARMACOKINETICSolvent/Active Compound : Ginkgo biloba extract (GBE)Type of experiment : humanType of animal : -Type of study : Open trialN(Total) : -N(Treatment) : -Sex : -Age : -Route : Oral administrationDose/Conc.(herb) : -Duration : -Type of interaction : PharmacokineticsInteraction with drug : Midazolam*/Versed/DormicumDose/Conc.(drug) : -Result : PositiveRemark : The pupose of study was to assess the ability of single midazolam concentrations to predict midazolam AUC in the presence and absence of CYP3A modulation by GBE. Subjects received oral midazolam 8 mg before and after 28 days of GBE administration. The geometric mean raio (90% confidence intervals) of midazolam AUC 0-infinity - GBE / AUC 0-infinity pre - GBE was 0.66 (0.49-0.84) P = .03). Single midazolam concentrations between 2 and 5 hours correctly predicted the reduction in midazolam AUC following GBE exposure, but confidence intervals were generally wide.Note : Data incomplete.
Part Used : ใบActivity : EFFECTS ON PHARMACOKINETICSolvent/Active Compound : -Type of experiment : humanType of animal : -Type of study : Cross overN(Total) : 14*N(Treatment) : 7**Sex : -Age : -Route : Oral administrationDose/Conc.(herb) : Voriconazole 200 mg after administration of Ginkgo biloba 120 mg twice daily.Duration : 12 daysType of interaction : PharmacokineticsInteraction with drug : VoriconazoleDose/Conc.(drug) : -Result : EquivocalRemark : * Healthy and nonsmoking volunteers. ** CYP2C19 extensive metabolizers (2C19*1/2C19*1). Results: For extensive metabolizers, the median value for voriconazole area under the plasma concentration time cruve from zero to infinity (AUC0-infinity) was 5.17 microgram/mL after administration of voriconazole alone and 4.28 microgram/mL after voriconazole with Ginkgo biloba (p>0.05). The other pharmacokinetic parameters of voriconazole such as AUC0-24, time to reach maximum concentration, half-life, and apparent clearance also did not change significantly for expensive metabolizers in the presence of Ginkgo biloba.Note : - 2 phase randomized crossover study with 4 weeks washout between phases. - Data incomplete.
Part Used : ใบActivity : EFFECTS ON PHARMACOKINETICSolvent/Active Compound : -Type of experiment : humanType of animal : -Type of study : Cross overN(Total) : 14*N(Treatment) : 7**Sex : -Age : -Route : Oral administrationDose/Conc.(herb) : Voriconazole 200 mg after administration of Ginkgo biloba 120 mg twice daily.Duration : 12 daysType of interaction : PharmacokineticsInteraction with drug : VoriconazoleDose/Conc.(drug) : -Result : EquivocalRemark : * Healthy and nonsmoking volunteers. ** CYP2C19 poor metabolizers (2C19*2/2C19*2). Results: Pharmacokinetic parameters of voriconazole for poor metabolizers were similar pattern of extensive metabolizers.Note : - 2 phase randomized crossover study with 4 weeks washout between phases. - Data incomplete.
Part Used : ใบActivity : EFFECTS ON PHARMACOKINETICSolvent/Active Compound : Ginkgo biloba extract (GBE)Type of experiment : humanType of animal : -Type of study : Open trialN(Total) : 10N(Treatment) : 10Sex : MaleAge : 21-27 yearsRoute : Oral administrationDose/Conc.(herb) : Talinolol 100 mg with a single oral dose of GBE 120 mgDuration : 24 hoursType of interaction : PharmacokineticsInteraction with drug : TalinololDose/Conc.(drug) : -Result : NegativeRemark : Result: A single oral dose of GBE did not affect the pharmacokinetics of talinolol. Primary constituents of ginkgo include flavonoids were reported to be substrates and modulators of P-glycoprotein. Further studies are required to identify whether quercetin and kaempferol are active substances in GBE to inhibit P-glycoprotein in humans.Note : - The pharmacokinetics of oral talinolol were determined after administration of a 100 mg tablet of talinolol at 24 hours in a 3-stage sequential study. The first tablet of talinolol was given on day 1 of the study. The second tablet was taken on day 8 with a single oral dose of a GBE 120 mg tablet. On days 9 through 22, same dose of a GBE was ingested by each subject 3 time daily. The final tablet of talinolol was taken on day 23, wtih 44th dose of GBE. - Healthy subjects.
Part Used : ใบActivity : EFFECTS ON PHARMACOKINETICSolvent/Active Compound : Ginkgo biloba extract (GBE)Type of experiment : humanType of animal : -Type of study : Open trialN(Total) : 10N(Treatment) : 10Sex : MaleAge : 21-27 yearsRoute : Oral administrationDose/Conc.(herb) : Talinolol 100 mg with after 14 days of repeated GBE ingestion (360 mg/day)Duration : 24 hoursType of interaction : PharmacokineticsInteraction with drug : TalinololDose/Conc.(drug) : -Result : NegativeRemark : Result: Repeated ingestion of GBE increased the talinolol maximum plasma concentration (C max) by 36% (90% Cl 10-68; p=0.025), the area under the concentration-time curve (AUC)0-24-by 26% (90% Cl 11-43; p=0.008) and AUC0-infinity by 22% (90% Cl 8-37; p=0.014), respectively, without significant changes in elimination half-life and the tin to Cmax.Note : - The pharmacokinetics of oral talinolol were determined after administration of a 100 mg tablet of talinolol at 24 hours in a 3-stage sequential study. The first tablet of talinolol was given on day 1 of the study. The second tablet was taken on day 8 with a single oral dose of a GBE 120 mg tablet. On days 9 through 22, same dose of a GBE was ingested by each subject 3 time daily. The final tablet of talinolol was taken on day 23, wtih 44th dose of GBE. - Healthy subjects.
Part Used : รากActivity : EFFECTS ON PHARMACOKINETICSolvent/Active Compound : Ginkgo biloba extract (GBE)Type of experiment : humanType of animal : -Type of study : Open trialN(Total) : 10N(Treatment) : 10Sex : MaleAge : 21-27 yearsRoute : Oral administrationDose/Conc.(herb) : Talinolol 100 mg with after 14 days of repeated GBE ingestion (360 mg/day)Duration : 24 hoursType of interaction : PharmacokineticsInteraction with drug : TalinololDose/Conc.(drug) : -Result : NegativeRemark : Result: Repeated ingestion of GBE increased the talinolol maximum plasma concentration (C max) by 36% (90% Cl 10-68; p=0.025), the area under the concentration-time curve (AUC)0-24-by 26% (90% Cl 11-43; p=0.008) and AUC0-infinity by 22% (90% Cl 8-37; p=0.014), respectively, without significant changes in elimination half-life and the tin to Cmax.Note : - The pharmacokinetics of oral talinolol were determined after administration of a 100 mg tablet of talinolol at 24 hours in a 3-stage sequential study. The first tablet of talinolol was given on day 1 of the study. The second tablet was taken on day 8 with a single oral dose of a GBE 120 mg tablet. On days 9 through 22, same dose of a GBE was ingested by each subject 3 time daily. The final tablet of talinolol was taken on day 23, wtih 44th dose of GBE. - Healthy subjects.
Part Used : ใบActivity : EFFECTS ON PHARMACOKINETICSolvent/Active Compound : -Type of experiment : in vivoType of animal : ratType of study : -N(Total) : -N(Treatment) : -Sex : -Age : -Route : Oral administrationDose/Conc.(herb) : -Duration : 8 daysType of interaction : PharmacokineticsInteraction with drug : Phenytoin*/Diphenylhydantoin/DPHDose/Conc.(drug) : -Result : PositiveRemark : Ginkgo biloba pretreated rats increased the bioavailability of phenytoin by 2.08 fold when compared with control.Note : - Pretreatment 7 days with noni juice or Ginkgo biloba, on day 8 the phenytoin was co-administrered orally with noni juice or Ginkgo biloba and the serum pharmacokinetics were determined at various time options (1, 2, 4, 6, 8, 12 and 24 hours) by HPLC. - Data incomplete
